



FLAT DOSES OF ANTI-PD1: WHAT IS THE ECONOMIC IMPACT?

A.MEURANT, G.MICHEL, V.MORIN-LEGIER, R.DELPLANQUE
Pharmacie, Hôpital Jacques Monod, 29 Avenue Pierre Mendès France, 76290 Montivilliers
meurant.alex@gmail.com

Background

In 2018 the European Summary of Product Characteristics (SPC) of **Opdivo®** (nivolumab) and **Keytruda®** (pembrolizumab) used in monotherapy were modified :

Weightbased doses → Flat doses

Purpose

We studied the **economic impact of these changes in posology** at the level of our hospital.

Material and methods

We selected patients treated by :


- Opdivo® for a **melanoma or a non-small cell lung cancer** (NSCLC)
- Keytruda® for a **melanoma**

The patients selected were currently treated with a weightbased dose, then with a flat dose after modification of the SPC. For each patient the economic impact associated with the change of dose was quantified.

Results


Opdivo®

Estimated annual cost for 28 patients
currently treated by Opdivo®



Keytruda®

Estimated annual cost for 6 patients
currently treated by Keytruda



Conclusion

Economic impact of the flat doses now recommended → **↗ € 120 000 a year**

The toxicity data with superior doses are reassuring, but **no clinical benefit is demonstrated**. Benefits on the safety side and on the organisation side with flat doses appear debatable in view of the derived additional costs.

This approach could be applied to the posology of **Keytruda® as first line of the NSCLC**. A weight-based dose would decrease the cost by **€ 378 000 per year** for our hospital, with **11 patients** currently treated.